Global Macro Strategist, Westbourne Research Services

Sharmila Whelan

Sharmila Whelan is a seasoned Global Geopolitical-Macro Strategist with nearly three decades of experience advising buy-side clients on multi-asset investment strategies and asset allocations. Her career has been defined by her differentiated thinking, a deep understanding of the interlinkages between

Westbourne Research Services Global Macro Strategist, Sharmila Whelan
global geopolitics, macro and policy dynamics and Austrian business cycle approach to economic analysis. Sharmila has extensive experience in both developed and emerging markets, particularly in China and India, and a proven track record of accurately forecasting investment risks and opportunities ahead of consensus.

Global Macro Strategist

A-H Premium Weekly (Jan 17th): Innocare Pharma, China Eastern Airlines, Air China

A-H Premium Weekly (Jan 10th): Zoomlion, Livzon Pharm, CEA, CanSinoBIO

A-H Premium Weekly (Jan 3rd):TEC, CanSinoBIO, SD GOLD, CRRC.

Macroeconomic, Geopolitical and Policy Forecasting

Westbourne Research Services

Westbourne Research is a global macroeconomic, geopolitical and policy forecasting and strategic advisory consultancy. Located in London, UK and serving clients globally. Our knowledge is deep, spanning all asset classes and key industrial sectors. Our perspective is global. Our presence is expansive, with 30 years analysing and working in developed and emerging markets. We are uniquely India and China specialists.

Cross Asset Strategy

Multiple Countries / Cross Asset Strategy

<ul>
<li>Stay underweight Chinese equities, sell the renminbi. The Chinese corporate profit cycle is worsening , signalling that the  economy Is yet to bottom.</li>
<li>Loss making companies were up 11% YoY in the first 11 months  of 2024 and accounted for 25% of manufacturing. </li>
<li>Operating revenues have held-up, but operating costs are rising fast as are inventories and liabilities. Corporate debt to GDP had already hit 295% in 3Q24.</li>
</ul>


Stay underweight Chinese equities, sell the renminbi. The Chinese corporate profit cycle is worsening , signalling that the  economy Is yet to bottom.
Loss making companies were up 11% YoY in the first 11 months  of 2024 and accounted for 25% of manufacturing. 
Operating revenues have held-up, but operating costs are rising fast as are inventories and liabilities. Corporate debt to GDP had already hit 295% in 3Q24.


Reasons To Underweight China